Introduction: Drug discovery is a challenging endeavor requiring the interplay of many different research areas. Gathering information on ligand binding thermodynamics may help considerably in reducing the risk within a high uncertainty scenario, allowing early rejection of flawed compounds and pushing forward optimal candidates. In particular, the free energy, the enthalpy, and the entropy of binding provide fundamental information on the intermolecular forces driving such interaction.
Introduction
The usual work-flow in drug discovery starts from either computational or experimental high-throughput screening programs, and progressing promising compounds from in vitro testing to assessing ADMET (absorption, distribution, metabolism, excretion and toxicity) properties and efficacy in preclinical animal models. The final goal in drug discovery is the identification of a chemical compound that, by interacting with a certain target, triggers a physiological response that results in the reversion of a pathological scenario caused by an aberrant activity of the target.
The chemical compound must fulfil rigorous constraints: good pharmacokinetic properties (suitable distribution through the body, as well as appropriate metabolic modification and clearance) and low toxicity (low level of interaction with unwanted secondary targets). Improving binding affinity while improving or maintaining drug-like properties is not an easy task.
According to Paul Ehrlich's statement "corpora non agunt nisi fixata" (a substance is not effective unless it is bound to another), the pharmacological action of a drug relies primarily on its interaction with the key target. Gathering the necessary information through the discovery process on ligand binding, in addition to information on pharmacokinetics and toxicity, and applying stringent filters in a rational way is instrumental for making appropriate decisions regarding ligand optimization. This will considerably reduce the attrition rate in the drug discovery process, allowing early rejection of flawed compounds and pushing forward optimal candidates. In order to increase the rate of success in the hit generation process, as well as in the hit-to-leadto-drug process, preclinical research in target validation and characterization, target selection, and, very importantly, integrated drug discovery strategies are crucial. Those integrated strategies involve applying multiple orthogonal approaches for obtaining valuable information and employing multifaceted decision criteria, where ligand binding thermodynamics may play a key role. Biophysical data, in particular thermodynamic binding information, provide information complementary to biochemical or cellular data, contributing to improve compound prioritization and decision-making in early stages in drug discovery. Importantly, biophysical techniques are key instruments for target characterization, screening design, and hit validation.
From a basic perspective, the drug-target interaction may be modeled as a simple equilibrium that can be characterized using binding equilibrium parameters and kinetic parameters. Although the kinetic information, epitomized by the recently established concept of residence time [1, 2] , represents an interesting approach for ligand optimization [3] , obtaining precise information on the equilibrium thermodynamics of the interaction is a crucial stage in drug discovery.
Traditionally, the main focus when quantifying binding affinity in drug discovery was set on determining binding parameters such as equilibrium constants (e.g., association, dissociation, and inhibition constants) and operational parameters (e.g., EC50 or IC50).
While the former parameters are true equilibrium constants, the latter operational parameters must be taken with caution since they do not represent true equilibrium constants, they are assay-specific and strongly dependent on experimental set-up and conditions, and they can very often lead to misinterpretations and considerable error when used for ranking compound affinities.
Besides binding affinity, the "reduced" set of thermodynamic ligand binding parameters (Gibbs energy, enthalpy, entropy and heat capacity) provides fundamental information on the interaction event and the intermolecular forces driving such interaction. These binding parameters can be measured directly (by isothermal titration calorimetry) or indirectly (e.g., by spectroscopy, surface plasmon resonance, or differential scanning calorimetry/fluorometry). Because we are interested in high quality information and the direct determination of binding parameters, avoiding if possible the estimation of binding parameters through secondary relationships (e.g., estimation of the binding enthalpy and the binding heat capacity through the van 't Hoff relationship in spectroscopic techniques), we will restrict this review to isothermal titration calorimetry (ITC). ITC is a technique especially suited for determining experimentally the "reduced" set of thermodynamic ligand binding parameters, as well as the "extended" set of thermodynamic ligand binding parameters (including linkage parameters associated with additional equilibria coupled to the ligand binding) [4] [5] [6] [7] .
Nowadays, the widespread availability of high-precision ITC instrumentation makes possible including binding thermodynamics into the drug discovery process.
As it will be explained below, the utility of the ligand binding thermodynamic profile (Gibbs energy, enthalpy, and entropy) in the drug discovery and ligand optimization process is based on the fact that it reflects and summarizes the interplay between numerous intermolecular interactions implicated in the formation of the drug-target complex: creation of the network of interactions between the drug and target, and rupture of interactions with the solvent, including the contribution of potential conformational and allosteric effects and additional equilibria coupled to the binding.
Intermolecular interactions of different nature (hydrogen bonds, van der Waals interactions, ionic pairs, hydrophobic interactions…) contribute differently to the binding affinity and, most importantly, to the binding enthalpy and entropy.
Incidentally, all intra-and intermolecular interactions are of electrostatic nature. However, traditionally, some special types of interactions have been named with specific terms:
hydrogen bond (a special type of ionic interaction), van der Waals interaction (the interaction between different combinations of instantaneous and permanent dipoles), ionic pair (purely electrostatic interaction between charged groups), hydrophobic interaction (the combination of van der Waals interactions between nonpolar groups and hydrogen bonds between surrounding water molecules), etc. The partition of the binding Gibbs energy into its enthalpic and entropic contributions reflects the mode of interaction between drug and target, i.e., intermolecular interactions responsible for the formation of the drugtarget complex, and molecular-scale phenomena taking place during the complex formation. This reveals an existing link between structural and functional features involved in the formation of the drug-target complex and the energetics of such process.
During lead optimization the binding affinity can be optimized by making the enthalpy of binding more favorable, the entropy of binding more favorable, or by a combination of both. Even though many combinations of enthalpy and entropy values will elicit the same binding affinity (i.e. the same Gibbs energy of binding and the same association constant), the properties and the response of the optimized compounds to changes in the environment or in the protein target are not the same. Besides, as we will discuss below, there are three main factors responsible for improving binding affinity from a thermodynamic point of view: 1) improving ligand-macromolecule interactions over those with the solvent in order to get a more favorable binding enthalpy; 2) making the ligand more hydrophobic in order to get a more favorable solvation entropy; and, 3) pre-shaping the ligand to the geometry of the binding site in order to minimize the loss of conformational entropy upon binding. On this basis, it was established that: 1) different optimization strategies based on chemically modifying the drug molecule would affect in a different extent the enthalpy and the entropy of binding (and, consequently, the Gibbs energy of binding); 2) the binding thermodynamic profile or signature of the drug molecule provides information on and conditions its optimization potential; and 3) enthalpic and entropic contributions to the Gibbs energy of binding reflect intermolecular interactions and molecular phenomena of different nature.
Consequently, the following hypotheses were made fifteen years ago: 1) an enthalpic optimization (improving the enthalpy of binding) of drug candidates is preferred over an entropic optimization (improving the entropy of binding); and 2) drug candidates with an enthalpically dominated thermodynamic binding profile represent the most promising compounds towards optimization regarding binding affinity, binding selectivity, and susceptibility to mutations in the target [8] [9] [10] [11] .
Enthalpic optimization relies on a rather simple idea: a large negative binding enthalpy is advantageous regarding binding affinity, target selectivity and ADME properties, because it reflects specific, direct, polar interactions between compound and target; on the other hand, large negative entropic contribution is disadvantageous, because it reflects mainly non-specific desolvation and van der Waals interactions [12] [13] [14] [15] .
Although different targets have been described to comply with these hypotheses (e.g., HIV-1 protease [11, 16] , plasmepsin II from P. falciparum [17] , HMG-CoA reductase [18] , this new paradigm for drug design and optimization based on integrating thermodynamic binding data and implementing an enthalpic optimization is not straightforward, requiring a carefully planned experimental strategy and a close data examination and analysis [19] .
Along recent years, it has been realized that reality could be not as simple as it was initially thought: enthalpic and entropic contributions integrate multiple contributions to the ligand-target complex formation (with a dominant role of water molecules), they are extremely sensitive to experimental conditions, and they are affected by enthalpy-entropy compensation [20, 21] . Therefore, the prospective use of thermodynamics in drug discovery (lead prioritization and optimization) could be somewhat intricate. In fact, it has been called into question very recently because of: 1) its apparent limited applicability to some "well-behaved" protein targets; 2) the retrospective nature of the underlying rationale and the apparent need of structural information; 3) a not so straightforward connection between structural/functional and energetic features associated to the drug-target interaction due to the multifactorial character of the enthalpic and the entropic of binding; and 4) the lack of guidance on how to prospectively use the thermodynamic profile in lead generation and optimization programs [22] . Thus, it seems that some of the expectations raised on the prospective application of binding thermodynamics in the selection and optimization of leads, in particular the improved success rate of preclinical drug discovery, have not been met. One of the purposes of this review is to draw the attention into this issue, and show how some weaknesses may be reverted into strengths.
It is obvious that, in principle, studying the binding thermodynamics of the drug-target interaction is an important but limited part of the drug discovery process; many other aspects (basically, those associated with pharmacokinetics and ADME properties) are apparently not related. However, as it will be commented below, valuable information on selectivity, adaptability and potential toxicity of a given drug can be linked to some ligand binding thermodynamics features. Besides, the biophysical techniques employed for providing information on the binding thermodynamics of the drug-target (mainly, ITC, but also many other experimental techniques) can be of help in designing and validating the experimental screening procedure, in establishing target engagement of potential lead compounds and performing secondary screenings, and in assessing selectivity and specificity of the interaction with the target by testing the interaction of lead compounds with potential secondary targets. The selection of a given experimental technique will depend on the information content, its throughput, its requirements for assay development, and its reagent consumption. ITC possesses several important advantages: direct determination of the thermodynamic binding profile in a single experiment, monitoring the interaction in solution, and universality of detection system based on reaction heat with no need for reactant modification. On the other hand, it has some considerable disadvantages: reagent consumption, and low throughput.
Over the past years biophysical techniques have been integrated as key components of drug discovery platforms. The use of biophysical techniques in drug discovery, the current status and the long term expectations, has been reviewed comprehensively 8 [23] [24] [25] . In this review, we will go first through the foundations of the thermodynamic description of ligand binding. Then, we will discuss: 1) what valuable information can be extracted from the ligand binding thermodynamic profile, 2) how this information can be used within a drug discovery program, and 3) what precautions and caveats must be taken into consideration when including that information within a drug discovery program.
Thermodynamics of ligand binding

The equilibrium constant
The reversible equilibrium between the free species of reactants, ligand L and macromolecule M, and the macromolecule-ligand complex, ML, is governed by the equilibrium association or dissociation constants, K a or K d :
Therefore, the ratio between the ligand-bound macromolecule and the ligand-free macromolecule and the ratio between the ligand-bound macromolecule and the total macromolecule are determined by the association constant and the concentration of ligand:
The equilibrium association constant is directly connected to the Gibbs energy of binding, the main thermodynamic potential at constant temperature and pressure:
where R is the ideal gas constant, and T is the absolute temperature. The required superscript "o" indicating standard conditions (1 mol/L, 298.15 K, 1 atm) has been omitted in Equation 3 and subsequent ones for the sake of clarity.
Additional thermodynamic potentials, the enthalpy and the entropy of binding, derive directly from the equilibrium constant or the Gibbs energy by introducing the temperature derivative:
which are the two additive terms making up the Gibbs energy: 
from the slope of the enthalpy vs. temperature plot.
When describing and comparing ligand binding profiles it is convenient to consider the entropic contribution to the Gibbs energy (-T∆S), instead of the entropy of binding (∆S). The reason behind that is to compare Gibbs energy, enthalpy and entropy on a common basis: with the same units (kcal/mol) and with the same criterion regarding spontaneity of the thermodynamic process (negative enthalpy and entropy contributions contribute favorably to the binding, while positive contributions oppose the binding). Thus, from now on whenever we refer to the entropy, we are actually referring to the "entropic contribution" (-T∆S).
If the ligand binding equilibrium is coupled to a conformational equilibrium, the apparent (or observed) association constant for the binding, K a app , is given by:
where K is the equilibrium constant corresponding to the conformational equilibrium between a non-binding competent conformation M* and the binding competent depending on whether L binds or not to the protein; in that case, the apparent association constant (and the apparent binding parameters) for ligand L exhibits a dependency on the pH (that is, the free concentration of ligand X):
where pK a,j is the acid dissociation constant for the protonation site j when ligand L is not bound to the macromolecule, and pK' a,j is the acid dissociation constant for the protonation site j when ligand L is bound. As another example, X may represent a competitive ligand for ligand L binding to the same site in the macromolecule; in that case, the apparent association constant (and the apparent binding parameters) for ligand L exhibits a dependency on the concentration of ligand X:
where K X is the association constant for ligand X (when ligand L is not bound to the macromolecule).
Though, in general, equation 8 may seem difficult to be used in practical terms, an interesting and very useful linkage relationship can be obtained by calculating the derivative of the apparent association constant for ligand L respect to the ligand X concentration [27, 30] :
where ∆n X is the net variation in the number of ligand X molecules bound to the macromolecule when ligand L binds to the macromolecule. Therefore, if ∆n X is equal to 
The Gibbs energy change
The Gibbs energy is the main thermodynamic potential in processes occurring at constant temperature and pressure, and it arises in a natural way when the second law of thermodynamics is applied to a closed system in thermal and mechanical equilibrium with its environment (at constant T and P). The Gibbs energy change in a process is the maximum reversible non-expansion work that may be performed by a given closed system in thermal and mechanical equilibrium with its environment, and is related to the change in total entropy (system plus environment). For a process to occur spontaneously the Gibbs energy difference between the final and initial states must be negative; in particular, for binding processes the Gibbs energy change is the difference in chemical potential between the complex and the free species:
where µ is the chemical potential of a given type of molecule.
Because in any spontaneous binding process the Gibbs energy change is negative (the more negative ∆G, the higher the binding affinity), there is more interest in focusing on and discuss the thermodynamics of binding in terms of its partition into the enthalpic and the entropic contributions, which may show positive or negative changes and exhibit higher susceptibility to changes in intrinsic and extrinsic factors (e.g., structural/functional alterations in the binding partners, changes in experimental conditions) than the Gibbs energy [32] , providing another layer of information on the binding process.
The enthalpy change
The enthalpy is a measure of the total energy in a system. At constant pressure, the enthalpy change in a system equals the energy exchanged with the environment through heat or non-expansion work; that is, the heat exchanged by the system a chemical reaction or by external heat transfer.
In binding process the enthalpy change reflects the net formation and disruption of many non-covalent interactions (hydrogen bonds, van der Waals and electrostatic interactions) between the two binding partners and the solvent, with the latter playing a key role establishing specific interactions and unspecific interactions. As indicated above, the overall enthalpy change (apparent or observed enthalpy of binding) can be split into the intrinsic enthalpy change plus the contributions from all possible coupled equilibria:
and, in a more specific way:
where ∆H int is the intrinsic enthalpy (enthalpy change associated with the formation of , and, therefore, differences observed between similar compounds may reflect specific changes in the contributions that can be engineered during the ligand optimization procedure. It is usual to group the intrinsic enthalpy and the desolvation enthalpy (and even the conformational enthalpy) into an "effective" binding enthalpy when approaching ligand optimization; being the other contributions important, they may be similar for the series of compounds or they may not be amenable to be engineered. Thus, the binding enthalpy can be considered a direct reflection of the interactions established between the binding partners to form the complex, the interactions broken with the solvent during desolvation (and the intramolecular interactions related to conformational changes).
Especial mention merits the coupling of proton exchange upon macromolecule-ligand complex. Because the experimental assay is performed with a buffered solution, the buffer molecule will be involved in any proton exchange in order to maintain constant the pH. The apparent association constant and the apparent Gibbs energy of the ligand will not be affected by the ionization properties of the buffer as long as its pK a is close enough to the experimental pH. But there will be a contribution to the binding enthalpy from the de/protonation of the buffer, which is an extrinsic contribution to the binding and could even dominate the apparent binding enthalpy [26, 33] :
where ∆H buffer is the ionization enthalpy of the buffer, and ∆H 0 is the bufferindependent binding enthalpy (all other contributions). Thus, it is possible to remove the contribution from the buffer de/protonation by performing titrations with buffers with different ionization enthalpies. Very importantly, the factor ∆n H is the same as 
The entropy change
The entropy is a measure of the distribution of energy over the different energy levels and degrees of freedom in a given system. It is also considered a measure of the randomness or disorder within the system. As it occurs with the enthalpy change, the entropy change can be factorized into different contributions:
where -T∆S desolv is the desolvation entropy (entropy change associated with the disruption of non-covalent interactions between the binding partners and hydration water molecules), -T∆S conf is the conformational entropy (entropy change associated with the conformational changes, in the ligand and the macromolecule, coupled to ligand binding), -T∆S ex is the ligand exchange entropy (entropy change associated with the exchange, association or dissociation, of other additional ligands upon ligand binding, such as ions, protons, small molecules…), -T∆S rt is the roto-translational entropy (entropy change associated with the formation of a complex from two molecules with independent translational and rotational degrees of freedom), and -T∆S vib is the vibrational entropy (entropy change associated with vibrational mobility in covalent bonds in both binding partners).
Similar to the binding enthalpy, differences observed between congeneric compounds may reflect specific changes in the contributions that can be engineered during the ligand optimization procedure. It is usual to mainly focus on the desolvation entropy and the conformational entropy when approaching ligand optimization.
The heat capacity change
The heat capacity change is a measure of the ability to store thermal energy in a given system. It is also considered a measure of the fluctuations in the enthalpy of the system. As it occurs with the other parameters, the heat capacity change can be factorized into different contributions:
where ∆C P,desolv is the desolvation heat capacity, ∆C P,conf is the conformational heat capacity, ∆C P,ex is the ligand exchange heat capacity, ∆C P,rt is the roto-translational heat capacity, and ∆C P,vib is the vibrational heat capacity (heat capacity associated with covalent bond vibrational modes in the interacting molecules).
Although the heat capacity of macromolecules is dominated by the vibrational contribution, the change in the heat capacity upon ligand binding is usually dominated by the desolvation contribution [38] [39] [40] , with a significant but small contribution originated from electrostatic interactions [41] . This binding parameter is extremely useful for assessing conformational changes coupled to ligand binding or characterizing the role of water molecules incorporated into the binding interface.
However, in this review we will focus on the Gibbs energy, the enthalpy and the entropy of ligand binding.
Thermodynamics in Drug Discovery: Binding
The thermodynamic binding profile: Basics
The measured binding parameters are apparent parameters containing contributions The desolvation of binding partners involves the disruption of interactions between water molecules and polar groups from the target and the drug, and also water-water hydrogen bonds in molecules surrounding nonpolar groups. The desolvation is accompanied by an unfavorable enthalpy (a larger enthalpic penalty in polar groups, ∼8 kcal/mol, compared to nonpolar groups, ∼0.7 kcal/mol, due to disruption of interactions [42] ), and a favorable entropy arising from the increased translational and vibrational mobility in the released water molecules. Interestingly, the desolvation entropy for polar groups is more favorable than that for nonpolar groups [42] . Of course, in the case some water molecules may become trapped into the binding interface, these will contribute with a favorable enthalpy and an unfavorable entropy.
The conformational adaptation of the binding partners may range from loop reorganization in the macromolecule or rotatable bond restraint in the drug, to complete refolding of the macromolecule binding domain. While the enthalpy associated to the conformational change may be favorable or unfavorable, the entropy associated is usually unfavorable (although some individual contributions to the conformational entropy might be favorable [43] , e.g., increase in flexibility in a certain region in the macromolecule upon ligand binding).
Finally, the formation of drug-target interactions relies on establishing hydrogen bonds and van der Waals and electrostatic interactions between drug and target. This is accompanied by a favorable enthalpy and an unfavorable entropy.
Summarizing, the overall binding entropy is dominated mainly by the large and favorable desolvation entropy associated with release of water molecules, and the unfavorable conformational entropy associated with the reduction in mobility of drug and target. On the other hand, the overall binding enthalpy is dominated by the large and unfavorable desolvation enthalpy (disruption of interactions with water) and the favorable interaction enthalpy (formation of drug-target interactions) (Figure 1 ).
The thermodynamic binding profile: Interpretation
From this basic description it is obvious that the enthalpy and entropy of binding Obviously, the two scenarios are completely different and the two ligands will differ in optimization potential, in binding selectivity and adaptability and drug-like quality.
Thermodynamic profiles may be used to reveal different, alternative binding modes (outliers from the expected profile).
The thermodynamic binding profile: Optimization
From a thermodynamic point of view, the contributions to the Gibbs energy of binding that are more informative regarding the mode of interaction of the ligand, as well as more susceptible to be engineered during ligand optimization are (Figure 1 ): the effective binding enthalpy (intrinsic binding enthalpy and desolvation enthalpy), desolvation entropy, and conformational entropy. Drawing the attention to the binding entropy, the lead binding affinity can be improved by increasing the desolvation entropy (more hydrophobic by adding nonpolar groups; however, as commented before, the desolvation entropy of polar groups is more favorable [42] ) and reducing the conformational entropy (pre-shaped to the binding site); additionally, the enthalpic penalty due to desolvation of nonpolar groups is reasonable small [42, 44] . This has been the dominant optimization paradigm during the last decades, and, consequently, there is a tendency of new drug candidates to be excessively hydrophobic [45] ; however, as explained below, this may have important drawbacks regarding solubility, bioavailability, and binding selectivity, diminishing the quality of the drug candidate. The question is: why has this happened? The answer is: because adding hydrophobic groups and structurally rigidifying the ligand molecule (entropic optimization) is much easier than adding polar groups for establishing distance-and orientation-dependent strong interactions with the target (enthalpic optimization). In principle, many combinations of binding enthalpy and entropy give rise to the same certain value of the binding affinity, however, an enthalpic ligand does not interact with the target in the same way as an entropic ligand does, even if they exhibit the same affinity: the former is attracted towards the target that provides an appropriate environment for satisfying energetic and functional constraints, whereas the latter just hides from water. Some drug-related properties, besides binding affinity, are directly linked to the enthalpy/entropy partition of the binding Gibbs energy. In addition, when optimizing leads already in the high affinity range, the possibility to optimize binding affinity with any combination of enthalpy and entropy is limited considering the constraints in the finite ensemble of chemical functionalities in small molecules, the different origin of enthalpic and entropic contributions, and the additional limitations imposed for maintaining or improving drug-like properties. Hence, when working at the high affinity range, it is desirable to avoid or minimize unfavorable contributions to the Gibbs energy and some degree of correlation between binding affinity and binding enthalpy arises.
As a conclusion, because the thermodynamic profile conditions the compound properties and the enthalpic optimization is difficult, starting from enthalpic hits or leads may seem advantageous and advisable; moreover, employing an enthalpic optimization strategy may be beneficial in early-medium stages in the drug discovery process because it will determine the drug quality of the compound, and entropic optimization can be performed in late-stage optimization [15] . The development of inhibitors against HIV-1 protease is an example of the expected benefits from using thermodynamics in drug design. The first HIV-1 protease inhibitors for clinical therapy were approved between 1995 and 1997. However, it took 12 years to develop secondgeneration inhibitors with improved binding affinity, binding selectivity, adaptability to drug-resistance associated mutations, and lower toxicity. One of the most striking conclusions from this study is the gradual, but dramatic, improvement in enthalpy:
"first-in-class" inhibitors exhibit an unfavorable or small favorable enthalpy (entropically driven binding), while "best-in-class" inhibitors exhibit a large and favorable binding enthalpy (enthalpically driven binding) [46] , a result also found for other targets like HMG-CoA reductase [18] and farnesyl pyrophosphate synthase [47] . 
Thermodynamics in Drug Discovery: Drug-like Properties
LipE
Among the many parameters employed as efficiency metrics to describe and rank ligand binding, lipophilic efficiency, LipE, is attracting much attention nowadays [50] :
where P is the octanol/water partition coefficient. Thus, LipE links binding affinity and hydrophobicity (or lipophilicity) in a single parameter and it is used in drug design and drug discovery to evaluate the quality of compounds and druglikeness. LipE quantifies the proportion of binding affinity that cannot be attributed to hydrophobicity (i.e., originated from polar groups). In practice, pK d can be substituted by pIC50 or pEC50, but, as commented above, IC50 and EC50 suffer from severe drawbacks. Similarly, logP can be substituted by logD (considering neutral and ionized species), and in practice they can be substituted by their computational estimations ClogP or ClogD. On one hand, high potency is a desirable attribute in drug candidates. On the other hand, hydrophobicity is linked to reduced solubility, bioavailability, and binding selectivity, as well as increased toxicity, thus increasing the risk of ADMET-related attrition [51] [52] [53] [54] .
Increasing LipE results in improved binding affinity and ADMET properties [55, 56] .
Theoretically, because: 1) polar groups contributing to the binding affinity also contribute to the binding enthalpy, and 2) polar groups exhibit low hydrophobicity, it is reasonable to expect a correlation between LipE and binding enthalpy. Interestingly, it has been shown experimentally that LipE correlates with binding enthalpy in many targets [57] [58] [59] . Thus, high LipE compounds exhibit the characteristic behavior associated with enthalpically driven binding (high selectivity, favorable ADMET properties), whereas low LipE compounds exhibit the characteristic behavior associated with entropically driven binding (low selectivity and impaired ADMET properties). That correlation may be founded on reasonable theoretical grounds [57] , considering some assumptions (e.g., the binding entropy is dominated by the solvation entropy or the conformational entropy is similar for a given set of compounds);
however, this connection has been questioned recently [22] .
Binding selectivity
Binding selectivity is instrumental for avoiding drug binding to unwanted targets. Offtarget binding results in side-effects and toxicity. As indicated above, high hydrophobicity in leads may be linked to selectivity loss and high binding promiscuity.
On the contrary, an enthalpic ligand will show considerable binding selectivity, because its binding is driven by polar, specific interactions [60] . Experimental examples have been found for the correlation between binding selectivity and binding enthalpy:
compounds stabilizing the transthyretin tetramer [61] , second-generation HIV-1 protease inhibitors [48] , MMP12 inhibitors [62] , and cannabinoid receptor ligands [63] .
It has been found experimentally that, during the lead optimization process, the addition of a polar group establishing strong hydrogen bonds usually result in a small or negligible binding affinity improvement (large enthalpy gain is compensated by large entropy loss), an example of the enthalpy-entropy compensation phenomenon in drug discovery [64] . On the contrary, the addition of a nonpolar group very often results in a moderate binding affinity improvement (small enthalpy change is largely compensated by a large entropy gain). As indicated above, these two facts summarize the empirical foundations for the traditional lead optimization strategy based on the entropic optimization: use of nonpolar groups and conformational rigidification of ligand structures as main engineering tools. Non-polar functionalities are easier to engineer and result in moderate affinity improvements, but at the cost of diminishing the quality of the drug regarding solubility, bioavailability and selectivity. While polar functionalities are much more difficult to engineer (although their desolvation entropy is more favorable than that of nonpolar groups, there is a need to compensate the desolvation enthalpy penalty and overcome the enthalpy-entropy compensation), they increase the quality of the drug, being those functionalities the dominant driving force in second-generation or best-in-class drugs [46] .
Enthalpy-entropy compensation is one of the main obstacles in drug discovery and development, and in the implementation of the enthalpic optimization of leads. The most difficult task is the introduction of polar groups (which ones? where?). After binding, polar groups may become: 1) exposed to the solvent and act as solubilizing elements of hydrophobic compounds; 2) desolvated, but not establishing strong interactions with the target; 3) desolvated establishing strong interactions with the target, but not contributing to binding affinity (due to enthalpy-entropy compensation); and 4) desolvated establishing strong interactions with the target and contributing to binding affinity (overcoming enthalpy-entropy compensation) [65] .
Polar groups from category 2 should be eliminated immediately in the optimization process. Polar groups from category 4 must be directed towards structured, low mobility regions in the target, in order to avoid a conformational entropy loss upon binding and overcome the enthalpy-entropy barrier. Interestingly, polar groups from category 3 and 4 may contribute to binding selectivity, independently of their contribution to binding affinity [65] . The reasoning behind this fact relies on: 1) the large desolvation enthalpy penalty from polar groups; and 2) the specific differences in the location of key functional groups in the binding site of similar targets. Thus, an enthalpically optimized compound possesses carefully positioned polar groups, specifically mapping complementary groups in the target to achieve large favorable binding enthalpy. In a secondary target with a slightly distinct binding site, suboptimal match between certain complementary groups will result in unproductive desolvation and a less favorable, or even unfavorable, binding enthalpy, severely diminishing the binding affinity. On the other hand, an entropically optimized compound has fewer configurational constraints and a lower dependence from its environment (the compound is pushed towards the binding site by water). Kawasaki and Freire have delineated a strategy to improve binding selectivity through structural/functional modification of the lead: if binding selectivity is to be improved by increasing the binding affinity for the primary target more than that for secondary targets, nonpolar functionalities must be incorporated into the lead; on the contrary, if binding selectivity is to be improved by decreasing the binding affinity for the secondary targets more than that for the primary target, polar functionalities must be incorporated into the lead [65] . It is obvious that these two alternatives will modify the thermodynamic binding profile of the lead in a different fashion.
In general, selectivity does not require high affinity [23] . Binding affinity and binding selectivity are not correlated: binding affinity is related to the quality (strength, contribution to the overall Gibbs energy, as well as the partition into enthalpic and entropic terms) of polar interactions, while binding selectivity is related to the spatial configuration of polar interactions. Polar groups establishing good interactions in the binding interface will compensate their large desolvation enthalpic penalty with their intrinsic enthalpy and their desolvation entropy (high quality polar interactions), while polar groups establishing poor interactions in the binding interface will not compensate their large desolvation enthalpic penalty with their intrinsic enthalpy and their desolvation entropy (thus, not contributing to the binding or even decreasing the binding affinity). Therefore, a high affinity ligand may exhibit low binding selectivity, while a moderate affinity ligand may exhibit a high binding selectivity. In fact, given that the selectivity indexes for similar targets are usually not larger than 1000, an extremely large binding affinity for the primary target may be detrimental for binding selectivity, because the binding affinity towards off-targets will still be considerable at the typical therapeutic dose of the drug [60] . Therefore, the best drug is not the compound with higher binding affinity, but the compound with sufficient binding affinity for eliciting the sought therapeutic effect, while exhibiting good pharmacokinetic and pharmacodynamic properties.
Binding adaptability
Binding adaptability is a concept apparently opposed to binding selectivity. Some targets require high target selectivity, while in other cases, because of natural/induced diversity or redundancy, adaptive drugs able to keep sufficient binding affinity for a set of homologous targets are required. For example, three of the most important adverse effects in HIV therapy based on protease inhibitors are: 1) side effects due to inhibition of secondary host targets, 2) the emergence of drug-resistant strains less susceptible to inhibitor action, and 3) the natural genetic diversity of HIV giving rise to coexisting multiple viral genotypes and subtypes. Then, adaptive drugs able to maintain enough binding affinity to distorted binding sites in the mutant or variant strains, but at the same time, able to maintain reduced binding affinity towards other host proteases are desirable. The proposed lead optimization strategy relies on the fact that mutations in the primary target occur at random only at certain residue locations, while key functional residues remain unchanged. Therefore, inhibitors must be engineered to establish strong interactions with conserved and more stable regions in the target and to find suboptimal complementarity in secondary targets providing binding selectivity, and to contain rotatable and asymmetric groups interacting with variable and less stable regions providing binding adaptability; entropic penalty associated with conformational flexibility in the ligand is compensated with the additional favorable binding enthalpy [11, 16, 48, 66, 67] .
Allostery
Ligand binding is very often coupled to considerable conformational changes. It is not 
Thermodynamics in Drug Discovery: Caveats
The previous section is full of optimistic statements about the application of thermodynamics in lead selection and optimization. However, extreme care should be taken when using thermodynamic binding profiles.
The binding process is a superposition of multiple microscale phenomena showing compensatory and cooperative effects, and binding enthalpy and entropy originate from multiplicity of intermolecular interactions [73] . Factorizing a thermodynamic binding profile into individual contributions is not trivial and rationalizing thermodynamic binding profiles may become a difficult task [74] . Careful reporting of experimental conditions in published work cannot be overemphasized.
Enthalpy-entropy compensation and cooperative energetic coupling between water molecules, functional groups in the ligand and intrinsic dynamics in the macromolecule may render quite difficult the interpretation of a given thermodynamic profile [75] . In particular, it has been shown that water molecules may considerably alter the thermodynamic binding profile, even if the effect on the Gibbs energy is small [76] .
Thus, interactions expected to be dominated by the hydrophobic effect show a large, favorable binding enthalpy: polyproline recognition by SH3 domains [77] , allophenylnorstatine-based inhibitors of the HIV-1 protease [36, 67] , and inhibitors of aldose reductase [78] .
Although enthalpy-entropy compensation, a formidable barrier to overcome in drug discovery, is a pervasive phenomenon in ligand binding [79] , the correlation between enthalpy and entropy can be artificially enhanced by an incorrect experimental strategy where additional extrinsic equilibria are not taken into account, bad quality experimental data, and a defective data analysis procedure [80, 81] .
In protein folding a good correlation between structural parameters (e.g., changes in solvent-accessible surface area) with energetic parameters has been established.
However, this has been not the case in ligand binding, mainly due to the small size and wide structural diversity of ligands. Moreover, contrary to what happen in protein folding, the probability of establishing suboptimal interactions in ligand binding is high.
Structural similarity in ligands (or in targets) does not necessarily result in similarity in binding energetics and allosteric effects, because intrinsic binding parameters may be differentially combined with contributions from coupled equilibria, water molecules, binding dynamics, or cooperativity between functional groups. Thus, the structural/functional determinants for binding affinity do not necessarily coincide with those required for eliciting cooperativity effects and allosteric responses: two similar ligands may exhibit different thermodynamic profiles and different allosteric and cooperativity effects with a given target [82] [83] [84] , and a given ligand may exhibit different thermodynamic profiles and different allosteric and cooperativity effects with two homologous targets [85] .
Conclusions
Biophysical techniques, in particular calorimetry, are important in the preclinical stage in drug discovery. They can be used for target characterization, screening validation, 
Expert opinion
How can we maximize likelihood of success and minimize risk in drug discovery? By integrating as much information as possible through orthogonal approaches: gathering biochemical, thermodynamic, kinetic, structural, and preclinical information alongside computational simulations. ITC is the gold-standard for characterizing biological interactions. Besides providing the "reduced" thermodynamic binding profile for a
given drug-target interaction, ITC gives access to many energetic aspects (the "extended" thermodynamic binding profile), very often overlooked when attention is restricted to the Gibbs energy [86] . In the past the thermodynamic binding profile has been employed retrospectively, together with structural information, as a guiding tool for lead optimization. Nowadays there is a quite strong foundation for using it prospectively in conjunction either with structural tools or within structure-activity relationship studies. Enthalpic ligand screenings can be routinely performed [87] , and algorithms for implementing an enthalpic (or entropic) optimization are available [88] . Empirical rules for improving binding affinity, selectivity, and adaptability on an energetic basis have been Nobody can deny the initial expectations on the application of thermodynamic methods in drug discovery have not been met. But we may wonder whether the methodology is flawed and inefficient because it is just based on a few anecdotal observations and our understanding of binding thermodynamics is not sufficiently advanced, or the methodology may seem quite complex and cumbersome resulting in considerable reluctance from researchers to integrate it within drug discovery programs. Although the throughput of ITC is not high, instrumentation for satisfying the needs at medium scale, for secondary screenings or for sets of lead derivatives, is available, methodologies for increasing the quality and the throughput of experimental data have been developed (e.g., single-injection titration [90] ), and empirical rules with reasonably solid foundations have been established to be applied on any potential target. Of course, it is not a straightforward task, but nobody said it was easy.
Article highlights box
• The thermodynamic binding profile (Gibbs energy, enthalpy and entropy of binding)
provides a wealth of information on the lead-target interaction due to the high sensitivity of the apparent binding parameters to intrinsic and extrinsic factors.
• Thermodynamic ligand binding data seem to be underutilized in lead selection and optimization in drug discovery programs, and it may prove fundamental for the discovery of new drugs and the reduction of attrition rates when used in combination with biochemical, kinetic, structural, preclinical, and computational data.
• Traditionally lead optimization has been accomplished by optimizing binding entropy: increasing hydrophobicity and conformational rigidity in the ligand. This usually results in poor drug-like ADMET-related properties (e.g., solubility, bioavailability, toxicity).
• Binding enthalpy is related to binding affinity, selectivity, adaptability and drug-like properties. In particular, binding enthalpy seems to be correlated with lipophilic efficiency, a commonly used index for lead optimization rewarding binding affinity and penalizing hydrophobicity.
• Enthalpic optimization leads to better prioritization and optimization of leads, facilitating binding selectivity and adaptability, without compromising other druglike ADMET-related properties.
• The use of thermodynamic binding profiles requires carefully planned experimental strategy, high-quality experimental data, and good data analysis procedures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. 
Declaration of interest
